Correlation of molecular genetic analysis of p53, MDM2, P16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma

被引:30
作者
Ushio, Y
Tada, K
Shiraishi, S
Kamiryo, T
Shinojima, N
Kochi, M
Saya, H
机构
[1] Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 860, Japan
[2] Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 860, Japan
关键词
anaplastic astrocytoma; glioblastoma; survival; p53; MDM2; p16; PTEN; EGFR; review;
D O I
10.2741/865
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This article reviews studies on the correlation between genetic abnormalities in malignant astrocytic tumors and patient survival. It is almost certain that alterations of PTEN on chromosome 10 represent a significant unfavorable prognostic factor in glioblastoma patients. The association of alterations in p53, MDM2, p16 or EGFR with the survival of patients with anaplastic astrocytoma or glioblastoma remains controversial. It is possible that the p16 alteration and EGFR amplification are associated with poor survival in certain groups of patients and that there might be a relationship with age. Malignant transformation of astrocytic cells are driven by the sequential acquisition of genetic alteration. Therefore, it is reasonable to subgroup gliomas by their patterns of genetic alterations. However the studies that correlated the multiple genetic alterations with survival are still limitted. Further studies on large cohorts are necessary to elucidate the genetic factors that affect the prognosis and response to therapy of patients with malignant gliomas and to develop effective management strategies.
引用
收藏
页码:E281 / E288
页数:8
相关论文
共 108 条
[1]  
Alleyne CH, 1999, INT J ONCOL, V14, P1111
[2]   EGFR overexpression and radiation response in glioblastoma multiforme [J].
Barker, FG ;
Simmons, ML ;
Chang, SM ;
Prados, MD ;
Larson, DA ;
Sneed, PK ;
Wara, WM ;
Berger, MS ;
Chen, PC ;
Israel, MA ;
Aldape, KD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (02) :410-418
[3]   Amplification and overexpression of MDM2 in primary (de novo) glioblastomas [J].
Biernat, W ;
Kleihues, P ;
Yonekawa, Y ;
Ohgaki, H .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (02) :180-185
[4]   Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas [J].
Burns, KL ;
Ueki, K ;
Jhung, SL ;
Koh, J ;
Louis, DN .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (02) :122-130
[5]   New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway [J].
Cantley, LC ;
Neel, BG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4240-4245
[6]  
Chakravarti A, 2002, CANCER RES, V62, P200
[7]   A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors [J].
Chernova, OB ;
Somerville, RPT ;
Cowell, JK .
ONCOGENE, 1998, 17 (22) :2873-2881
[8]  
Costello JF, 1996, CANCER RES, V56, P2405
[9]   The multiple roles of PTEN in tumor suppression [J].
Di Cristofano, A ;
Pandolfi, PP .
CELL, 2000, 100 (04) :387-390
[10]   PTEN mutations in gliomas and glioneuronal tumors [J].
Duerr, EM ;
Rollbrocker, B ;
Hayashi, Y ;
Peters, N ;
Meyer-Puttlitz, B ;
Louis, DN ;
Schramm, J ;
Wiestler, OD ;
Parsons, R ;
Eng, C ;
von Deimling, A .
ONCOGENE, 1998, 16 (17) :2259-2264